SCM
PTCT icon

Silverarc Capital Management’s PTC Therapeutics PTCT Stock Holding History

Silverarc Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,389
Closed -$3.08M – 80
2025
Q1 		$3.08M Buy
+60,389
New +$3.01M 0.63% 45

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silverarc Capital Management's PTCT Position: Q2 2025 in Review

Silverarc Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 60,389 shares — an estimated $3.08M sold.

Silverarc Capital Management first reported a position in PTCT in Q1 2025 and held it in 1 quarter. The position peaked at $3.08M in Q1 2025. 284 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Silverarc Capital Management reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 60,389 PTC Therapeutics shares in Q2 2025, an estimated $3.08M.
  • Silverarc Capital Management first reported a position in PTC Therapeutics in Q1 2025 and held it in 1 quarter.
  • Silverarc Capital Management's PTC Therapeutics position peaked at $3.08M in Q1 2025.
  • 284 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.